Advertisement

Topics

OTEZLA® (Apremilast) Phase II Data Showed Clinically Meaningful Improvements in Patients with Active Ulcerative Colitis

09:30 EST 15 Feb 2018 | Businesswire

This article has expired, however you can still download the PDF.
Preview:
Data shared at the 13th Congress of ECCO Phase III program with OTEZLA (apremilast) in ulcerative colitis expected to begin in 2018 Celgene Corporation (NASDAQ:CELG) announced that data from a randomized, ...

Other Sources for this Article

Investors:
Patrick E. Flanigan III, 908-673-9969
Corporate Vice President, Investor Relations
or
Media:
Catherine Cantone, 908-897-4256
Senior Director, Corporate Communications

NEXT ARTICLE

More From BioPortfolio on "OTEZLA® (Apremilast) Phase II Data Showed Clinically Meaningful Improvements in Patients with Active Ulcerative Colitis"

Advertisement
Quick Search
Advertisement
Advertisement

 

Relevant Topics

Clincial Trials
In a clinical trial or interventional study, participants receive specific interventions according to the research plan or protocol created by the investigators. These interventions may be medical products, such as drugs or devices; procedures; or change...

Drug Discovery
Clinical Approvals Clinical Trials Drug Approvals Drug Delivery Drug Discovery Generics Drugs Prescription Drugs In the fields of medicine, biotechnology and pharmacology, drug discovery is the process by which drugs are dis...